HCPCS Level II
J9261
Injection, nelarabine, 50 mg
Codes near J9261
These sit next to J9261 in the CMS Level II file. All J codes
- J9255Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg
- J9256Injection, nipocalimab-aahu, 3 mg
- J9258Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
- J9259Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
- J9260Injection, methotrexate sodium, 50 mg
- J9262Injection, omacetaxine mepesuccinate, 0.01 mg
- J9263Injection, oxaliplatin, 0.5 mg
- J9264Injection, paclitaxel protein-bound particles, 1 mg
- J9265Injection, paclitaxel, 30 mg
- J9266Injection, pegaspargase, per single dose vial
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00078-0683-61 | Arranon | Sandoz Inc. | 5 |
| 25021-0259-50 | Nelarabine | Sagent Pharmaceuticals | 5 |
| 25021-0259-51 | Nelarabine | Sagent Pharmaceuticals | 30 |
| 39822-0650-01 | Nelarabine | XGen Pharmaceuticals DJB, Inc. | 5 |
| 39822-0650-06 | Nelarabine | XGen Pharmaceuticals DJB, Inc. | 30 |
| 43598-0142-06 | Nelarabine | Dr. Reddy's Laboratories Inc. | 30 |
| 43598-0142-11 | Nelarabine | Dr. Reddy's Laboratories Inc. | 5 |
| 62332-0813-50 | Nelarabine | Alembic Pharmaceuticals Inc. | 5 |
| 66758-0165-94 | Arranon | Sandoz Inc. | 5 |
| 70121-1743-04 | Nelarabine | Amneal Pharmaceuticals, LLC | 30 |
| 70710-1726-01 | Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 5 |
| 70710-1726-08 | Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 30 |
| 70710-1839-01 | Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 5 |
| 70710-1839-08 | Nelarabine | Zydus Pharmaceuticals (USA) Inc. | 30 |
| 71288-0165-53 | Nelarabine | Meitheal Pharmaceuticals Inc. | 30 |
| 71288-0165-54 | Nelarabine | Meitheal Pharmaceuticals Inc. | 5 |
| 72205-0154-01 | Nelarabine | Novadoz Pharmaceuticals LLC | 5 |
| 72205-0154-04 | Nelarabine | Novadoz Pharmaceuticals LLC | 30 |
| 81927-0111-01 | Nelarabine | Shorla Oncology Inc. | 5 |
| 81927-0111-06 | Nelarabine | Shorla Oncology Inc. | 30 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.